Antibe Therapeutics, Inc.

Antibe Therapeutics, Inc.

August 22, 2005 07:00 ET

Antibe Therapeutics Announces Appointments of New President/CEO and CFO

CALGARY, ALBERTA--(CCNMatthews - Aug. 22, 2005) - Antibe Therapeutics Inc., an early-stage drug development company, is pleased to announce the appointments of Daniel Legault as President and Chief Executive Officer and Alain Wilson as Chief Financial Officer of the Company.

Daniel Legault brings extensive strategic management experience to Antibe, having led a number of fast growing companies. He is a founding principal of Revelstoke Partners, a Toronto-based merchant bank focused on assisting companies in challenging situations, ranging from sophisticated, later-stage startups approaching commercialization to more mature but under-performing companies. Prior to founding Revelstoke Partners, Dan was President of Opal Sky, the pioneering CRM strategy and technology services company, and the President of Butterfield & Robinson, the renowned high-end tour operator. Dan is on the Board of Directors of Green Shield Canada, one of the country's largest health and drug benefits insurers, and Save the Children. Dan obtained his law degree at Queen's University, and is a Member of the Law Society of Upper Canada and the New York Bar.

Alain Wilson brings to Antibe extensive experience in international strategic and financial management across a number of different industries. He is also a founding partner of Revelstoke Partners prior to which he had an extensive career in management consulting. Alain was the Office Head of Mercer Management Consulting in Toronto. Alain also brings experience in the software and services business, co-founding and serving as Chief Operating Officer for a leading CRM solutions provider. Alain obtained a B. Comm. at Queen's University and an MBA at IMD in Switzerland.

Antibe's founding President and CEO, Dr. John Wallace, remarked: "Dan Legault and Alain Wilson bring tremendous management and leadership skills to Antibe Therapeutics and will be instrumental in facilitating the further development of our lead compounds and in achieving a favourable exit for our investors. We are also pleased to establish a new office in the heart of Canada's primary financial district". Dr. Wallace will undertake the role of Chief Scientific Officer and will remain as Chairman of the Board of Directors.

About Antibe Therapeutics: Antibe (pronounced 'on-teeb') is a privately held, early-stage drug development company with offices in Calgary and Toronto and laboratories in the US, the UK, Italy and Brazil. The Company's pipeline includes drugs targeting serious chronic diseases characterized by inflammation, pain and/or vascular dysfunction including pulmonary hypertension, erectile dysfunction, Crohn's disease and colitis, irritable bowel syndrome, asthma and various complications of diabetes.

Contact Information